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ABSTRACT
Asthma is a disease of usually reversible airways
obstruction that has prominent inflammation of the
mucosa as an underlying feature. It is a disease of
varying severity, with some individuals suffering from
only occasional symptoms and others having daily
symptoms and requiring large doses of inhaled and
oral corticosteroids. Although the different forms of
asthma have some common pathological features, 
the extent of change varies from mild to severe forms.
The only cell type that has been widely correlated 
with disease severity has been the eosinophils, but it is
evident that altered function and responsiveness of 
T cells to steroids plays a key role as a determinant of
asthma severity. More recently, attention has focused
on restructuring of the airways, which results in, or
possibly develops in parallel with, inflammation. 
This restructuring consists of changes throughout the
bronchial wall, beginning with changes in the epi-
thelium, increased collagen deposition, increased
microvasculature, hypertrophy and hyperplasia of
submucosal glands, goblet metaplasia within the 
epithelium, hypertrophy and hyperplasia of smooth
muscle and, finally, poorly defined changes in the
adventitia. Novel treatments have been, and continue
to be, developed to target specific components of
inflammation and remodeling. However, to date, none
has lead to a marked improvement in disease control
and further efforts are needed to better understand the
mechanisms of asthma, in particular those that are not
responsive to corticosteroids.
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INTRODUCTION
The use of bronchoscopy as a research tool has markedly
improved our understanding of the pathology of asthma.
Airway inflammation is a feature of all forms of this
disease, irrespective of whether it is related to atopy,1–5
occupation6 or has no known cause (often referred to as
intrinsic or non-atopic asthma).7 Varying degrees of
airway inflammation are seen across the range of asthma
severity and the characteristics of the cellular infiltrate
vary markedly between mild and severe forms. Following
initial studies of mild asthmatics,1–4 there has been an
increasing effort to improve the understanding of the
pathology of asthma and its functional implication in
moderate and severe forms. The need to do this has
become particularly evident with the growing apprecia-
tion of the relative ineffectiveness of the available
anti-inflammatory drugs used in the treatment of this
disease.
EOSINOPHILS AND MAST CELLS AS EFFECTOR
CELLS IN ASTHMA: HOW IMPORTANT ARE THEY?
A number of cell types participate in the complex cell
network that typifies asthma. Of these, the cell that has
been associated longest with the disease and, indeed,
with many other forms of atopic disease has been the
eosinophil. Initially, eosinophils were believed to be
beneficial by controlling allergic inflammation through
their ability to degrade histamine and stop its release, 
in addition to inactivating leukotrienes and platelet
activating factor (PAF). Subsequently, fairly abundant
information was generated to implicate these cells as
prominent effector cells and the cells were thus seen as
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being responsible for many of the inflammatory res-
ponses in both asthma and allergic rhinitis.8 The
combination of studies using induced sputum and bron-
choalveolar lavage (BAL),5,9–11 to study the products of
cells residing in the airway lining fluid, and bronchial
biopsy,1,12 to characterize the cellular infiltrate in the
epithelium and the deeper submucosal layer, has invari-
ably shown increased numbers of eosinophils in asthma
throughout the bronchus. Many, although not all, have
shown an association with dieases severity and bronchial
hyperresponsiveness.11,13 This has led to the notion that
asthma is a form of eosinophilic bronchitis.
The number of eosinophils in BAL is relatively low.
Eosinophils rarely exceed 5–10% of the total cell count
due to dilution of the recovered cells from the bronchi by
cells washed out from the alveoli, which contain few
eosinophils and numerous macrophages.14,15 Eosinophil
counts are much higher in induced sputum,9–11 presum-
ably because this technique predominantly samples the
proximal airways. Eosinophils are also more abundant
in the mucosa.1,12 Comparison of BAL and sputum
eosinophil counts on the one hand and mucosal counts
on the other shows poor correlation between these two
compartments, possibly due to quantitative and/or quali-
tative differences between the mechanisms responsible
for the accumulation and survival of these cells.
Even the very mild, intermittent forms of asthma,
requiring only occasional use of bronchodilators, are
characterized by prominent sputum eosinophilia.11 In
biopsies, studies have shown that eosinophil counts are
also raised in atopic non-asthmatics suffering from aller-
gic rhinitis.2 This suggests that a low-grade degree of
eosinophilic bronchial inflammation is a feature of atopy
in general and that the degree of mucosal eosinophilia
may determine the likelihood of functional impairment of
the airways. However, the physiological relevance of sub-
clinical eosinophilia is unclear because these individuals
are unlikely to develop any sequalae that would lead to
restructuring of the airways and reduced lung function. It
is also important to note that there are diseases, such as
Crohn’s disease, where raised eosinophil counts are seen
in sputum but are not associated with either respiratory
problems or hyperresponsiveness.16
In asthma, eosinophils are in an activated state and
secrete increased amounts of arginine-rich proteins, such
as eosinophil cationic protein (ECP), eosinophil peroxi-
dase (EPO) and major basic protein (MBP), which can
detected in BAL and induced sputum.11,15,17,18 All these
proteins are stored in the granule matrix, except for MBP,
which is contained within the crystalline core that is
identified as an electron-dense crystal structure by the
electron microscope.8 In contrast with the healthy state, in
which sputum ECP levels rarely exceed 20 ng/mL, in
asthma, concentrations as high as 650 ng/mL can be
detected.11 Exposure to allergen in the laboratory leads to
further elevations in ECP during the late-phase asthmatic
response.17 These basic proteins are toxic to the epithe-
lium;19 together with the pressure exerted by mucosal
edema, this is thought to lead to epithelial damage.
Consistent with raised levels of ECP and MBP in BAL fluid
of asthmatic patients,15 electron microscopic investi-
gation of the eosinophil granule ultrastructure shows
dissolution of both the granule matrix and the crystal
core. This is seen as marked heterogeneity in the appear-
ance of eosinophil granules, with swelling of the
granules, and dissolution of the both the core and
matrix.1 As further evidence of eosinophil degranulation,
immunohistochemical analysis shows prominent deposits
of both ECP and MBP in areas of epithelial damage of
asthmatic lungs.20 In addition, it is now appreciated that
eosinophils also produce an array of cytokines and
chemokines. Some of these (interleukin (IL)-3, IL-5 and
granulocyte–macrophage colony stimulating factor 
(GM-CSF)) act in an autocrine manner to promote
eosinophil maturation, activation and survival.8 Others,
such as IL-16 and RANTES, promote recruitment of
eosinophils and T cells. Regulatory cytokines IL-2, IL-4
and IL-10 conceivably contribute to the control of T cell
activation, proliferation and cytokine generation. Thus, in
addition to causing immediate damage to the epithelium,
bronchoconstriction, vasodilatation and mucus hyper-
secretion, eosinophils have their own capability to
promote chronic inflammation.
The mechanisms leading to accumulation of eosino-
phils in the airways have been a topic of great interest.
Eosinophil chemotactic activity can be readily demon-
strated in induced sputum.11 A number of studies using
BAL conducted in the mid-1980s have shown that stimu-
lation with allergen using inhalation challenge leads to
increased infiltration and degranulation of eosinophils in
the lumen, especially in subjects who develop so-called
dual (early and late)-phase asthmatic responses.17,21,22
These observations have now been confirmed in biopsy
studies.23 Allergen exposure during the pollen season
leads to an increased release of chemokines.24 The 
influx of eosinophils is associated with increased expres-
sion of intercellular adhesion molecule (ICAM)-1 and
E-selectin23 on mucosal post-capillary venules and an
early accumulation of neutrophils and lymphocytes, all of
which points to a complex upregulation of inflammatory
processes involving a host of chemotactic factors and
adhesion molecules. Several chemotactic factors have
been identified, including PAF,25 leukotrienes26 and chemo-
kines, such as eotaxin,27 RANTES24 and monocyte
chemotactic protein (MCP).28
When considering the role of eosinophils in chronic
disease, it has been of particular interest to study these
cells in severe disease. The first study gave somewhat sur-
prising and contradictory results: although some patients
with severe asthma treated with oral corticosteroids had
raised eosinophils in bronchial biopsies, the majority did
not.29 Similar observations were made in another study.30
Subsequent careful characterization of a larger number
of patients found two groups that were felt to be different
in respect to their pathology.31 One group had raised
eosinophils whereas the other did not; patients with
eosinophils had evidence of mast cell activation,
increased T cell infiltration and raised collaged deposi-
tion, all pointing to a role of persistent eosinophilia as
either a marker or determinant of severe asthma.
The final proof of the importance of a cell or mediator
comes with the development of specific drugs that inhibit
their effects. Recent clinical trials involving either IL-1232
or anti-IL-5 antibodies,33 both of which have been effec-
tive at almost totally depleting the airways of eosinophils,
have been surprisingly negative. This has placed an
important question mark about the role of eosinophils in
asthma. In neither of these studies did treatment with 
IL-12 or anti-IL-5 antibody ablate the late-phase asth-
matic response. This was very much in opposition to the
central role that has been attributed to eosinophils as
effector cells in allergen-provoked asthma. Ongoing
clinical trials are looking at disease activity in the natural
setting using two different anti-IL-5 antibodies. If these
manage to deplete the blood and airways of eosinophils
without improving the clinical symptoms of asthma, the
studies will further undermine the position for eosinophil
as a key player in asthma.
The other cell that has been viewed as being key in
allergic responses has been the mast cell. Mast cells have
long been associated with allergic diseases by way of
their ability to respond specifically to allergens cross-
linking IgE molecules bound to the cell surface via FcεRI
receptors. In non-asthmatic subjects, mast cells recov-
ered by BAL constitute a minority (0.04–0.6%) of the total
nucleated cells; in asthmatics, these numbers can be
increased as much as fivefold.34,35 However, even with
such an increase, mast cells still constitute only a minority
of the inflammatory cells in the lumen. Whereas mast cell
numbers are not necessarily raised in asthma,1,36 exami-
nation by electron microscopy shows extensive changes
in their granules, which have been associated with mast
cell activation.1 In support of ongoing mast cell mediator
secretion, levels of mast cell-derived mediators are raised
in BAL and induced sputum in asthmatics.11,37–40 As with
eosinophils, these changes are seen even in the mildest
forms of the disease. Allergen challenge in vivo leads to
mast cell activation and release of histamine, which can
be detected in BAL.38,41 This is associated with a rise in the
134 kDa neutral protease tryptase,38 a mediator found
almost uniquely in mast cells. Other mast cell mediators
that are important as effectors of bronchoconstriction
seen during the early asthmatic response (EAR) are
prostaglandin (PG) D2 and the sulfidopeptide leukotrienes.
Mast cells are a major source of sulphidopetide leuko-
trienes, which also increase vascular permeability and
are between 100- and 1000-fold more potent than hista-
mine and methacholine as contractile agonists. The past
few years have seen a particular interest in leukotrienes,
with the development of potent and selective antagonists
of either the 5-lipoxygenase enzyme or the leukotriene
(LT) D4 receptor, which have been shown to be effective
in abrogating the airway responses to exercise or allergen
challenge42 and improving clinical symptoms.43 Their effi-
cacy may be related to disease severity in view of the
limited evidence that expression of the 5-lipoxygenase
enzyme is normal in the airway mucosa of mild asthmat-
ics, but is raised in those with more severe disease.44,45
Tryptase has recently generated significant interest,
both as an important mediator in asthma and as a thera-
peutic target. In comparison with control subjects, in
whom tryptase is either undetectable or at very low levels
(< 2 ng/mL), concentrations as high as 40 ng/mL can be
detected in the induced sputum of asthmatics.11 However,
the range of concentrations of tryptase in sputum from
asthmatics is wide, suggesting that the extent of mast cell
involvement may vary, although there appears to be no
relationship with disease severity. Tryptase has been
shown to enhance airway smooth muscle responsive-
ness in dogs.46 It also degrades bronchodilator neuro-
peptides, such as the vasoactive intestinal peptide (VIP),47
and cleaves complement components, to form anaphyla-
toxins,48 and kininogen, to yield bradykinin and lysyl-
bradykinin.49 Tryptase also contributes to increased
microvascular leakage in the mucosa,50 which, together
with the capacity to chemoattract and activate eosinophils51
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and enhance the expression of ICAM-1 on epithelial
cells,52 serves to promote mucosal eosinophilia.
Of particular interest is the effect of tryptase on ICAM-1
expression and it can be speculated that similar effects
contribute to increased expression of this adhesion mole-
cule on a number of other cell types (T cells, eosinophils,
endothelial cells).11,23,53 A close correlation can be
demonstrated between the levels of tryptase and soluble
(s) ICAM-1 in induced sputum,11 which is in keeping with
the described tryptase-induced upregulation of ICAM-1
and IL-8 in epithelial cells.52 These observations have
pointed to tryptase as a major mediator of allergic reac-
tions and have prompted the development of therapeutic
agents that specifically target tryptase. One of these,
APC366, a specific tryptase antagonist, has been tested
in a sheep model of allergic airway responses and has
been shown to significantly attenuate the allergic res-
ponse in sheep.54 More recently, it has been shown that
premedication of asthmatic volunteers with nebulized
APC366 partially, but significantly, reduces the mag-
nitude of the allergen-induced late asthmatic response
(LAR).55
The importance of mast cell products is still uncertain.
A positive correlation found between airway responsive-
ness and the relative numbers of mast cells recovered by
BAL and sputum levels of histamine implies a role for
mast cells in perpetuating this pathophysiologic abnor-
mality.11,14,34 This observation has been extended in
studies that have shown that increased spontaneous hist-
amine release by BAL mast cells is seen only in those
subjects with increased airway responsiveness15 and that
the concentration of histamine in the cell-free super-
natant of BAL is related to the level of histamine
responsiveness.41 However, it is well appreciated that cro-
molyns, known for their mast cell stabilizing properties,
are poor at controlling asthma. In addition, treatment
with short-acting β2-adrenergic receptor agonists, which
are even more potent inhibitors of mast cell mediator
release, is ineffective at controlling inflammation. How-
ever, some recent studies with long-acting β2-adrenergic
receptor agonists have shown anti-inflammatory proper-
ties of these drugs;56 however, whether this is entirely
through inhibition of mast cells or some other, as yet
unknown factors, remains to be seen.
Mast cells are now also recognized for their capacity to
produce cytokines, the actions of which are of relevance
to the initiation and maintenance of allergic responses,
including IL-3, IL-4, IL-5, IL-6, GM-CSF and tumor necro-
sis factor (TNF)-α.57 Importantly, IgE-mediated triggering
of mast cells leads not only to secretion of stored
cytokines, but also results in their de novo generation.58
To what extent mast cells contribute to the overall genera-
tion of cytokines in asthma is uncertain. Staining of
adjacent 2 µm tissue sections embedded into glycol
methacrylate (GMA) resin localizes the majority of IL-4
protein to mast cells and a lesser proportion to eosino-
phils, but fails to detect IL-4 in T cells.58 This is in contrast
with studies using in situ hybridization to detect mRNA
transcripts for IL-4 and other T helper 2 (Th2)-type
cytokines, which show that the majority of cells positive
for IL-4 mRNA are T cells.4 One interpretation is that
there is a relatively high turn-over of IL-4 produced by 
T cells that, unlike mast cells, do not have a granular
storage capacity and use this cytokine as an autocrine
growth factor, promoting the development of Th2-type
CD4+ T cells. An important consideration is the fact that
only a minority of T cells in the airways are allergen spe-
cific, in contrast with mast cells, which all bear IgE and,
thus, can be stimulated directly by allergen.
It can be speculated that activation of IgE-bearing
mast cells and release of IL-4 may promote the differenti-
ation of Th0-type T cells into Th2-type T cells. However, it
remains to be seen whether this happens in the mucosa
or regional lymphoid tissue. The use of antibodies 
for immunohistochemical staining, which distinguishes
between stored and secreted IL-4, has been helpful in
demonstrating the ability of mast cells to generate
cytokines as part of allergic inflammation.58 The finding
of an increased proportion of mast cells displaying
peripheral ring staining for IL-4 protein with antibody
against the secreted form in stable asthma and further
increases in this staining pattern in bronchial biopsies of
pollen-sensitive asthmatics during the pollen season59
point to allergen-induced activation of mast cells to
secrete this central cytokine.
THE CENTRAL ROLE OF T CELLS IN ASTHMA
For an allergen (or, indeed, any antigen) to initiate an
inflammatory response, it needs to be presented by an
antigen-presenting cell (APC). Initially, this requires aller-
gen uptake, its processing (partial degradation) within the
APC, physical association with class II major histocom-
patibility complex (MHC) molecules and exteriorization 
of the antigen/MHC class II complex on the surface of 
the APC. Thereafter follows an interaction between the
complex and the antigen receptor on the T lymphocyte
(TCR) and between a number of accessory cell surface
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molecules (including lymphocyte function-associated
antigen (LFA)-1 and ICAM-1, CD40 and its ligand
CD40L, and CD28 and B7-1/B7-2) present on cells that
both recognize each other specifically and participate in
the process of cellular costimulation. In addition, cyto-
kines are produced that contribute to the overall response.
The interaction between APC and T cells during antigen
presentation may determine not only the extent of T cell
activation, but also the differentiated phenotype of the 
T cell.
Antigen presentation in the lungs is believed to be con-
ducted mainly by dendritic cells,60 which are considered
by some researchers as the only true professional APC.61
In both animal and human airways, dendritic cells, which
express high levels of MHC class II, are most prominent
within the airway epithelium, where they form an inter-
digitating network.62 The density of the intraepithelial
dendritic cell population is maintained in a steady state
by a balance between the recruitment of cells from the
blood and their egress to local secondary lymphoid
tissues where antigen presentation is believed to occur.
However, in response to a range of stimuli, including
inhaled viruses and soluble antigens, the density of
intraepithelial dendritic cells increases rapidly, but tran-
siently.63 Thus, even stable asthmatics can be seen to
have raised numbers of CD1α+ dendritic cells in the
airways mucosa.64 It is of relevance to asthma therapy
that the number of dendritic cells can be reduced by
treatment with inhaled corticosteroids.65
It is now widely recognized that T cells are able to influ-
ence the function of mast cells, eosinophils, epithelial
cells and fibroblasts, and these interactions are a major
focus of interest in asthma research. Unlike T cells of non-
allergic subjects, those of allergic patients with asthma,
atopic dermatitis and perennial rhinitis become activated
and proliferate when cultured in the presence of antigen
DerP1 of Dermatophagoides pteronyssinus, with the
degree of T cell proliferation correlating with specific IgE
levels.66 In both BAL67 and the mucosa3 of patients with
atopic asthma, T lymphocytes are in an increased state of
activation, with a greater proportion of cells expressing
the activation markers IL-2 receptor (IL-2R; CD25) and
the type II histocompatibility antigen HLA-DR on their
surface than non-atopic control subjects. In the mucosa,
the number of activated T cells has been shown to cor-
relate with the number of eosinophils and the degree of
bronchial responsiveness to methacholine.68 In exacerba-
tions of asthma, increased T lymphocyte activity has also
been noted in peripheral blood, as judged by the per-
centage of CD4+ T cells expressing IL-2R, HLA-DR and
the very late antigen (VLA)-1.69,70 Decreased expression
of these activation markers occurs in parallel with clinical
improvement, which could be attributed to corticosteroid
therapy given to treat exacerbations of asthma.
In severe corticosteroid-dependent asthma, there is a
further increase in activated T lymphocytes expressing 
IL-2R; this correlates with disease activity, as shown by
high variation in peak expiratory flow (PEF).29 Importantly,
this is seen despite the use of high doses of inhaled and
oral corticosteroids, suggesting a degree of corticos-
teroid resistance. It is now recognized that asthmatics
vary in their responses to corticosteroids. Furthermore,
these patients have evidence of raised IL-5 release into
the mucosa, but this is not necessarily associated 
with increased eosinophil counts.29 While the majority 
of patients respond to regular corticosteroid therapy, a
subset of patients have poorly controlled asthma, even
when treated with high doses of oral corticosteroids. 
In principle, all patients who are not fully controlled with
moderate doses of corticosteroids and have persistent
inflammation13 can be seen as having a degree of
corticosteroid unresponsiveness. Unresponsiveness to
corticosteroids can be demonstrated in the laboratory 
by studying the suppressive effects of dexamethasone 
on T lymphocyte proliferation induced by the mitogen,
phytohemagglutinin. True corticosteroid resistance, where
no suppressive effect is seen at all, is rare but relative
resistance to doses that are normally effective is not
uncommon and presents a problem in clinical practice.
Corticosteroid-resistant asthma can be defined by the
failure to improve baseline morning prebronchodilator
forced expiratory volume in 1 s (FEV1) by greater than
15% predicted following 7–14 days of 40 mg oral pred-
nisolone (20 mg twice daily or its equivalent).71 Although
some patients may respond to higher doses of pred-
nisolone given for longer periods, such doses are
undesirable because they can be associated with marked
side effects.
Most of the research into the role of T cells in asthma
has focused on the proinflammatory role of CD4+ T cells.
More recently, there has been increasing evidence that
CD8+ T cells may also have a role in asthma pathogene-
sis. It is now widely appreciated that purified CD8+ T cells
possess the capacity to produce a wide range of cyto-
kines and chemokines that, in some instances (interferon
(IFN)-γ, GM-CSF, macrophage inflammatory protein
(MIP)-1α, IL-16, and RANTES) exceeds that of CD4+
T cells. Distinct cytokine-secreting subsets of CD8+ T cells
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(Tc), similar to their CD4+ Th1 and Th2-type counter-
parts, have now been identified and designated Tc1 cells,
which secrete predominantly IL-2 and IFN-γ, and Tc2,
which secrete IL-4 and IL-5. Circulating CD8+ T cells
from asthmatic individuals have increased intracellular
concentrations of IL-4 compared with cells from non-
atopic healthy control subjects,72 although the mechanisms
of activation of these cells and the release of IL-4 and its
contribution to the overall allergic response remain
unknown. CD8+ T cells may play an important role in
response to virus infection, which can influence the gen-
eration of cytokines by these cells.73 This may be of
importance to both mild and, in particular, severe exacer-
bations of asthma in which increased numbers of CD8+
T cells accumulate in the airway mucosa.74
OTHER CELLS THAT MAY DETERMINE
ASTHMA SEVERITY
In an attempt to elucidate the mechanisms that determine
asthma severity, a number of researchers have studied
the events that occur during nocturnal asthma. While this
form of asthma usually reflects poor disease control,
genetic studies suggest that a Gly16 polymorphism of the
β2-adrenergic receptor, which may be responsible for
downregulation of receptor numbers, is more frequent in
nocturnal asthma, a form of asthma that is believed to
reflect more severe disease. Thus, genes may help deter-
mine the extent of disease severity. Bronchoscopic studies
conducted at night have shown an influx of eosinophils
into the airways and their release of ECP as demonstrated
by BAL.75 Of particular interest is the finding that promi-
nent changes occur in the lung parenchyma, which, so
far, has not been thought to be involved in asthma.76
Quantification of the cellular infiltrate shows an accumu-
lation of eosinophils in the alveolar tissue in the early
hours of the morning that is associated with increased
expression of Th2-type cytokines.
However, the other cell type that is now being consid-
ered as a candidate in more severe forms of asthma is the
neutrophil.13 As disease progresses, neutrophil counts
are also seen to increase compared with healthy control
subjects and patients with mild asthma, with several-fold
increases in both BAL and transbronchial biopsies in the
very severe forms of corticosteroid-dependent asthma.30
Neutrophils have so far not been thought to be important
in asthma and have been viewed as being more charac-
teristic of bronchitis. Increased airway neutrophilia is seen
in asthma exacerbations77 and in asthma deaths.78
Because both of these have been linked with infections,
neutrophilia has not been considered to be a feature of
the chronic allergen-driven component of the patho-
genesis of asthma. The mechanisms involved in recruiting
and activating neutrophils remain to be elucidated, but
initial studies point to raised LTB4,79 detected in BAL and
raised tissue levels of free IL-8 in the bronchial mucosa80
in severe forms of asthma as being possibly implicated by
attracting and activating neutrophils.
If neutrophils contribute to the disordered airway func-
tion, it is unclear which mechanisms are important. The
levels of myeloperoxidase (MPO) are not raised in
induced sputum in asthma, although both neutrophil
counts and MPO levels correlate with the levels of airway
hyperresponsiveness,81 suggesting that they are a marker
of some other neutrophil function that contributes to this
pathophysiologic abnormality. It has been suggested that
treatment with corticosteroids may be partly responsible
for increased neutrophil numbers and function.82–84
However, short-term treatment with inhaled cortico-
steroids does not change neutrophil numbers in sputum 
(R Djukanovic, unpubl. obs.). It may be that longer-term
corticosteroids may have an effect, although this remains
to be demonstrated.
At the extreme end of the spectrum of asthma severity
are patients who die during an asthma attack. At post-
mortem, their lungs are invariably hyperinflated and
remain so upon opening of the chest wall, reflecting
extensive bronchial obstruction. The presence of over-
whelming bronchospasm in the absence of mucus
plugging is probably rare, as suggested in a review of a
large number of cases of fatal asthma.85,86 Abundant
mucus plugs account for areas of atelectasis, which can
lead to segmental and even lobar collapse following
reabsorption of air distal to the site of bronchial obstruc-
tion. This points to hypersecretion by the hyperplastic
submucosal glands and, possibly, goblet cells within the
epithelium. Mucus plugging, leading to partial lung col-
lapse, can also be noted occasionally in living asthmatics,
especially in those suffering from allergic broncho-
pulmonary aspergillosis. The extent of mucus plugging in
fatal asthma has been estimated to result in more than
50% occlusion of the peripheral airways.87 The patho-
physiologic implications of mucus plugging in severe
asthma resulting in death are significant and the presence
of physical obstruction to airflow offers an explanation for
the ineffectiveness of bronchodilator drugs.
When scrutinizing the individual data from most studies
of patients with asthma, it is apparent that there is large
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variation in cell counts and mediators. Even when allowing
for methodologic problems of sampling, one cannot
ignore the observation that many patients with clinically
mild disease have abundant inflammation; others with
severe disease have little inflammation. Thus, it is clear
that there is a component of airway pathology that is
needed before disease can develop; this same com-
ponent may indeed determine the severity of the disease.
It is now increasingly believed that this airway restruc-
turing, usually referred to as airway remodeling, is that
component.
THE PROCESS OF AIRWAYS RESTRUCTURING
IN ASTHMA
Extensive morphological changes occur in asthmatic
airways as a consequence of chronic inflammation. The
existence of these changes has been long known in cases
of severe asthma,88 but is now also seen on mild forms of
the disease89 and even in atopic individuals without clini-
cal signs of asthma.2 The entire depth of the airway wall is
affected and the functional changes involve all the struc-
tural cells and the extracellular matrix.
The airway epithelium forms the first line of defence in
the lungs by providing integrity and protecting the airways
from environmental insults. It is composed of columnar
ciliated, secretory and basal cells. The epithelial cells are
organized into a stratified layer, with the columnar cells
resting on basal cells that are bound to the basement
membrane.90 Any loss of this protective barrier is likely to
have significant implications for the deeper mucosal
layers by causing leakage, either through the grossly
damaged epithelial layer or via breaks in the intercellular
tight junctions.
The interpretation of epithelial damage in biopsies
obtained by bronchoscopy has been controversial
because of possible artefactual, bronchoscopically
induced damage. Nonetheless, studies that have used
rigid bronchoscopy and large biopsy forceps, which are
less likely to cause artefactual damage than those used in
fibreoptic bronchoscopy, have demonstrated widespread
damage and shedding of the epithelium in asthma.
Studies of bronchoscopic biopsies and BAL suggest an
increase in the extent of epithelial sloughing as an inte-
gral part of the asthmatic process.15,36,91 These findings
are consistent with epithelial clumps seen in sputum and
described in the early literature as Creola bodies and
which have been reported to be increased in asthma,
especially during acute exacerbations.92,93
The mechanisms leading to epithelial damage have
not been fully elucidated. They probably involve a combi-
nation of mediators that are toxic to the epithelium, such
as the arginine-rich eosinophil-derived cationic proteins
and proteolytic enzymes,19,94 which results in a fault-line
between the columnar and basal cells,95 and upward
pressure from the edema of the submucosa. The damage
inflicted on the epithelial layer is usually not due to cytox-
icity, but appears to result from weakening of the
junctional adhesion structures.95 This results in a more
selective loss of columnar cells and relative preservation
of the basal cell layer. As a consequence, an increased
proportion of columnar cells are seen in clumps of two or
more cells.
Within the spectrum of airway diseases, damage of the
bronchial epithelium appears to be unique to asthma
and is not seen in chronic bronchitis, where squamous
cell metaplasia develops. While epithelial damage is
associated with attempts at repair, as suggested by
increased expression of the CD44 adhesion molecules in
areas of regeneration,96,97 this seems to be unable to lead
to complete restitution.98 Whether this is due to repeat
injury or impaired repair mechanisms is unclear. Damage
to the epithelium and the resulting repair cause a dysreg-
ulation of epithelial cell function, with the production of
mediators that can act on inflammatory as well as struc-
tural cells.98 Normally, communication between the
epithelium and fibroblasts occurs during morphogenesis
of the lung, which results in branching of the airways. This
interaction is referred to as the epithelial–mesenchymal
trophic unit, which appears to be highly abnormal in
asthma.98
The full implications of epithelial damage for asthma
pathogenesis are not known and are a focus of inten-
sive research. Theoretically, epithelial shedding should
remove the protective barrier that prevents the allergens
and microorganisms from damaging the deeper layers
and, at the same time, reveal the nerve endings. In
keeping with this notion, studies have shown that the
degree of epithelial cell loss correlates with the measured
level of airway hyperresponsiveness.15,36,91 In addition,
the epithelium participates in the secretion of IgA to
protect against microorganisms but, if anything, the levels
of IgA in sputum appear to be raised in asthma. The loss
of epithelial integrity results in increased permeability to
macromolecules. The epithelium also inhibits the action
of kinins via neutral endopeptidase effects and has
antioxidant enzymes that counter the effects of environ-
mental oxidants, such as ozone and nitrogen dioxide.99
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Through their capacity to generate endothelins and
lipoxygenase products of arachidonic acid, epithelial
cells can contribute to smooth muscle tone, which is
countered by the production of nitric oxide (NO), which
acts as a bronchodilator. However, an array of the medi-
ators produced by the epithelium are proinflammatory
(PGE2, NO, 15-hydroxyeicosatetraenoic acid (HETE),
endothelin, IL-1β, IL-6, IL-11, leukemia inhibitory factor
(LIF), GM-CSF, IL-16, and IL-18, IL-8, MIP-1α, MCP-3,
RANTES and eotaxin).98 Although, theoretically, slough-
ing of the layer of activated cells may act as a means of
downregulating inflammation, whether this is of physio-
logic relevance is unclear.
As part of the response to chronic injury, the reticular
layer of the basement membrane undergoes extensive
changes. Interstitial collagens type III and V, products of
myofibroblasts located beneath the true basement mem-
brane upon which the epithelial cells rest, are deposited
to form a dense and thickened layer.100 The extent of
collagen deposition correlates with the increase in the
number of myofibroblasts.100 Studies have shown that
both the superficial100 as well as the deeper layers100 of
the submucosa of asthmatic airways contain significantly
more collagen than is normal.
The increased production and deposition of collagen
involves a number of growth factors and cytokines, such
as transforming growth factor (TGF), platelet-derived
growth factor (PDGF), basic fibroblast growth factor
(bFGF), TNF-α, IL-4 and endothelin, in association 
with mast cell mediators tryptase and histamine. Several
growth factors may be released from inflammatory cells
in the airways, such as macrophages and eosinophils,
but also by structural cells, such as the airway epithelial
and endothelial cells and fibroblasts. Platelet-derived
growth factor is released from many different cells in the
airways and consists of two peptide chains, with A-A, B-B
or A-B dimers being secreted by different cells. These
dimers interact with α (AA) or β (AB or BB) receptors.
Macrophages release PDGF on activation.101 Platelet-
derived growth factor may activate fibroblasts to
proliferate and secrete collagen and may also stimulate
proliferation of airway smooth muscle,102 which is medi-
ated via the β receptor. The epithelium has now been
shown to be an important source of factors that promote
fibrosis, including PDGF, TGF-β and insulin-like growth
factor (IGF)-1.103,104 Indeed, there is now talk of the
epithelial–mesenchymal trohoic unit being abnormal in
asthma.105 During normal embryogenesis, the epithelium
and fibroblasts play a central role in lung development
through opposing forces that make the airways grow (by
way of epithelial proliferation) and bifurcate. This unit is
believed to become dormant after completion of lung
growth but, in disease, appears to be reactivated.
Supernatants from cultured human airway epithelial
cells stimulate the proliferation of human lung fibro-
blasts and this activity appears to reside predominantly 
in IGF-1.104 Transforming growth factor-β comprises a
family of growth-modulating cytokines that have an
important influence on the turnover of matrix proteins.106
They may either inhibit or stimulate proliferation of fibro-
blasts, depending on the presence of other cytokines.
Lung fibroblasts themselves may be a source of TGF-β,107
but it is also secreted by inflammatory cells, including
eosinophils and airway smooth muscle cells.103
However, the relative importance of these factors to
airway remodeling and their cellular source is far from
clear. A recent study has localized the major part of 
TGF-β to eosinophils.108 The increased number of
eosinophils has been shown correlate with reduced FEV1
and the latter correlated with the extent of subepi-
thelial fibrosis, pointing to a possible cause and effect
relationship.108
In parallel with collagen deposition, there are changes
in the other components of the extracellular matrix that
indicate destruction of the elastic support. Furthermore,
the appearance of α2 laminin chains, which are normally
seen during morphogenesis, points to an increased
turnover of the tissue matrix.109 Immunohistochemical
and electron microscopic analysis of elastin fibres in the
bronchial mucosa shows evidence of lysis and fragmen-
tation,110 even though the total content of elastic fibres
appears not to be different when comparing asthmatic
and normal lungs.111 Degradation of elastase could
result from activation of macrophages and eosinophils
and their release of elastase and other metallo-
proteases.112–115 This change does not appear to be
related to the use of corticosteroids, which are known to
inhibit the generation of elastic fibres.116 The pathophysi-
ologic consequences of elastic fibre degradation are
difficult to assess because the changes cannot be readily
quantified and correlated with pulmonary function. The
loss of elastic fibres is likely to make the airway less
distensible.117 Whether similar changes occur in the
bronchial adventitia and the parenchyma, where there
is now evidence of inflammatory cell involvement,76 is
uncertain, but the combination of airway and parenchy-
mal changes could account for the loss of elastic recoil in
asthma.118
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As a further component of airway restructuring due to
chronic inflammation and possibly repeated broncho-
constriction, the airways smooth muscle layer undergoes
hypertrophy and hyperplasia.88,119 In addition, prominent
hyperplasia of mucus glands in the airway wall can be
seen in cases of fatal asthma.120 Finally, recent studies
show an increase in the number of blood vessels in the
mucosa.121 Several cytokines and growth factors have
been shown to stimulate angiogenesis, including TNF-α,
IL-1 and bFGF.103 Recently, substance P has also been
found to have potent angiogenic effects.122 The structural
changes in airway smooth muscle may also result from
stimulation by PDGF and endothelin released from acti-
vated inflammatory cells in the airways.102,123,124 Even
mediators such as histamine are able to stimulate growth
in airway smooth muscle cells, as measured by the
increase in c-fos expression.125
Another feature of asthmatic remodeling that has
attracted recent interest has been the increased number
of blood vessels, which, in the mucosa, are of the post-
capillary venule type. These have been found both in
mild121 and severe126 asthma. Although these vessels may
not express increased amounts of adhesion molecules,
the increased surface area probably provides greater
interaction between circulating cells and the endothe-
lium, thus increasing cell accumulation in the mucosa.126
Initial studies suggest that treatment with corticosteroids
can reduce the number of blood vessels.127
How, exactly, the remodeling changes impact on airway
physiology is unclear. The changes observed under the
microscope find confirmation in studies using computed
tomography, which is able to demonstrate abnormalities
of the airway wall in a significant proportion of asthmat-
ics.128,129 In some studies, the changes can be related to
the duration and severity of asthma.130 Therefore, it seems
logical that airway remodeling should be a target for
asthma treatment and, indeed, a number of studies have
shown an increased rate of decline in lung function.131–133
However, it remains unclear which patients are at risk of
developing structural changes that are of physiologic rele-
vance and there are no cellular or physiologic predictors
for such a development. Nevertheless, long-term follow
up of asthmatic patients treated with either β2-adrenergic
receptor agonists alone or with β2-adrenergic receptor
agonists and inhaled corticosteroids has shown a clear
benefit of anti-inflammatory treatment in reducing the risk
of loss of airways function.134,135
Mechanical removal of epithelial cells in vitro results in
increased responsiveness of airway smooth muscle to
several spasmogens136 and suggests that epithelial cells
may release a relaxant factor analogous to endothelial-
derived relaxant factor in blood vessels. Thus, damage of
the epithelium would remove the protective effect of this
relaxant factor, leading to exaggerated bronchocon-
strictor responses. The nature of this putative relaxant
factor, termed EpDRF, is not certain, although it is not an
eicosanoid or NO. Its existence has been demonstrated
in superfusion experiments,137 but the effects of epithelial
removal on contractile responses to spasmogens is small
and the relevance of this phenomenon is not certain, par-
ticularly in vivo, when the labile factor would have to
diffuse across the submucosa and its blood supply to
reach airway smooth muscle. Perhaps this factor may
have a more important role as a vasodilator regulating
airway blood flow.
Loss of epithelial integrity may result in loss of
mediators that serve to counter the actions of bron-
choconstrictor agents. Epithelial cells strongly express
neuroendopeptidase (NEP),138 which is an important
enzyme in degrading various bronchoconstrictor pep-
tides, such as tachykinins, bradykinin and endothelin-1.
Mechanical removal of airway epithelium greatly poten-
tiates the bronchoconstrictor effect of tachykinins99 and
bradykinin,137 an effect that is mimicked by the NEP
inhibitor phosphoramidon. Several factors that lead to
exacerbations of asthma appear to downregulate the
function of epithelial NEP, including virus infections,
oxidants and toluene diisocyanate.139
Epithelial damage will also expose sensory nerve
endings, which may be activated by inflammatory media-
tors, leading to inflammation via an axon reflex mech-
anism.140 Epithelial cells themselves may release several
inflammatory mediators, such as 15-lipoxygenase prod-
ucts, which are chemotactic for inflammatory cells, PGE2,
which may protect against bronchoconstriction141,142 or
may sensitize sensory nerves endings, endothelin-1 and
NO.143,144
CONCLUDING REMARKS
With the abundance of information on the pathology of
asthma that we now possess, there is no doubt that we
have greatly improved our understanding of the patho-
genesis of this disease. However, we are no closer to
identifying the main factors that cause asthma and
sustain the chronic inflammation. Indeed, we do not
know whether the mechanisms involved in initiating the
disease and maintaining it are the same. Thus, elucidation
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of early events during the development of asthma 
are crucial if efforts are to result in preventative measures
that may alter the susceptibility of atopic individuals to
develop clinical asthma. Another main challenge is to
identify which cell types, signal transduction mechanisms
and nuclear transcription factors are the main players
in what is undoubtedly a complex cellular network. It is
almost certain that targeting and neutralizing a single
mediator or cell type is not going to arrest the asthmatic
process. Finally, further attempts have to be made to
improve our classification of asthma, which should be
based not only on descriptive pathology, but also on
common intracellular defects, so as to be able to target
more specifically the disease process.
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